中国药物经济学2024,Vol.19Issue(3) :68-71.DOI:10.12010/j.issn.1673-5846.2024.03.013

肝胆消炎片联合复方甘草酸苷注射液治疗铂类抗癌药致肝损伤的疗效

Curative Effect of Gandan Xiaoyan Tablet combined with Compound Glycyrrhizin Injection in the Treatment of Platinoid Anticancer Drug Induced Liver Injury

刘晓兰 潘萍 伍欣瑜
中国药物经济学2024,Vol.19Issue(3) :68-71.DOI:10.12010/j.issn.1673-5846.2024.03.013

肝胆消炎片联合复方甘草酸苷注射液治疗铂类抗癌药致肝损伤的疗效

Curative Effect of Gandan Xiaoyan Tablet combined with Compound Glycyrrhizin Injection in the Treatment of Platinoid Anticancer Drug Induced Liver Injury

刘晓兰 1潘萍 1伍欣瑜1
扫码查看

作者信息

  • 1. 江门市新会区中医院药剂科,广东江门 529100
  • 折叠

摘要

目的 探讨肝胆消炎片联合复方甘草酸苷注射液治疗铂类抗癌药致肝损伤的疗效.方法 选取2021 年1 月至2023年1 月江门市新会区中医院收治的60 例因铂类抗癌药致肝损伤患者作为研究对象,按照随机分组法分为观察组(n=30,肝胆消炎片联合复方甘草酸苷注射液治疗)和对照组(n=30,仅用复方甘草酸苷注射液治疗).比较两组临床疗效,治疗前后肝功能指标[血清总胆红素(TBIL)、丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)]、炎症因子[白细胞介素 6(IL6)、单核细胞趋化蛋白-1(MCP-1)、转化生长因子-β(TGF-β)、肿瘤坏死因子-α(TNF-α)]水平,治疗后生命质量以及治疗期间不良反应发生情况.结果 治疗后,两组TBIL、ALT、AST、IL6、MCP-1、TNF-α降低(P<0.05),且观察组TBIL、ALT、AST、IL6、MCP-1、TNF-α低于对照组(P<0.05);治疗后,两组TGF-β升高(P<0.05),且观察组TGF-β高于对照组(P<0.05);治疗后,观察组躯体功能(PF)、情绪功能(EF)、总健康状况(QL)评分高于对照组,疲倦(FA)、恶心与呕吐(NV)、疼痛(PA)、失眠(SL)、食欲丧失(AP)评分低于对照组,差异有统计学意义(P<0.05);两组角色功能(RF)、认知功能(CF)、社会功能(SF)、气促(DY)、便秘(CO)、腹泻(DI)、经济困难(FI)评分比较,差异无统计学意义(P>0.05);两组治疗期间不良反应发生率比较差异无统计学意义(P>0.05).结论 肝胆消炎片联合复方甘草酸苷注射液治疗铂类抗癌药致肝损伤临床疗效显著,可有效改善肝功能和炎症反应,提高患者生命质量,且不良反应较少,临床应用价值较高.

Abstract

Objective To explore the efficacy of Gandan Xiaoyan tablet combined with compound glycyrrhizin injection in the treatment of liver injury caused by platinoid anticancer drugs.Methods Sixty patients with liver injury caused by platinoid anticancer drugs admitted to Xinhui District Hospital of Traditional Chinese Medicine in Jiangmen City from January 2021 to January 2023 were selected as the study objects,and were divided into observation group(n=30,treated with Gandan Xiaoyan tablet combined with compound glycyrrhizin injection)and control group(n=30,treated with compound glycyrrhizin injection only)according to randomization method.The clinical efficacy,Liver function indicators[serum total bilirubin(TBIL),alanine aminotransferase(ALT),aspartate aminotransferase(AST)],inflammatory factors[interleukin 6(IL6),monocyte chemoattractant protein-1(MCP-1),transforming growth factor-β(TGF-β),tumor necrosis factor-α(TNF-α)]levels before,and after treatment Quality of life after treatment and adverse reactions during treatment of the two groups were compared.Results After treatment,TBIL,ALT,AST,IL6,MCP-1 and TNF-α were decreased in both groups(P<0.05),and TBIL,ALT,AST,IL6,MCP-1 and TNF-α in observation group were lower than those in control group(P<0.05).After treatment,TGF-β was increased in both groups(P<0.05),and TGF-β in observation group was higher than that in control group(P<0.05).After treatment,the scores of physical function(PF),emotional function(EF)and total health status(QL)in observation group were higher than those in control group,while the scores of fatigue(FA),nausea and vomiting(NV),pain(PA),insomnia(SL)and loss of appetite(AP)in observation group were lower than those in control group,with statistical significance(P<0.05).There was no significant difference in the scores of role function(RF),cognitive function(CF),social function(SF),shortness of breath(DY),constipation(CO),diarrhea(DI)and economic hardship(FI)between the two groups(P>0.05).There was no significant difference in the incidence of adverse reactions between the two groups during treatment(P>0.05).Conclusion Gandan Xiaoyan tablet combined with compound glycyrrhizin injection has significant clinical efficacy in the treatment of liver injury caused by platinum-based anticancer drugs,which can effectively improve liver function and inflammatory response,improve the quality of life of patients,and have fewer adverse reactions,and have high clinical application value.

关键词

药物性肝损伤/肝功能指标/炎症因子/肝胆消炎片/复方甘草酸苷注射液

Key words

Drug-induced liver injury/Liver function index/Inflammatory cytokines/Hepatobiliary Xiaoyan tablet/Compound glycyrrhizic acid injection

引用本文复制引用

基金项目

江门市卫生计划局科学技术研究项目(21A079)

出版年

2024
中国药物经济学
中国中医药研究促进会

中国药物经济学

影响因子:0.712
ISSN:1673-5846
参考文献量13
段落导航相关论文